{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:44:39Z","timestamp":1740177879936,"version":"3.37.3"},"reference-count":34,"publisher":"Instituto Nacional de Salud Publica","issue":"1, ene-feb","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Salud Publica Mex"],"abstract":"<jats:p>Objetivo. Evaluar la prevalencia de anticuerpos antiparotidi\u00adtis en ni\u00f1os y adolescentes de M\u00e9xico, a dos a\u00f1os de haberse introducido la vacuna SRP. Material y m\u00e9todos. Se estu\u00addiaron 2 111 ni\u00f1os (1-9 a\u00f1os) y 2 484 adolescentes (10-19 a\u00f1os). Se evaluaron anticuerpos IgG con un kit comercial de ELISA indirecto. Resultados. La seroprevalencia fue 70.6% (IC95% 69.3-71.9) y result\u00f3 mayor en adolescentes (83.0%, IC95% 81.5-84.5) que en ni\u00f1os (56.0%, IC95% 53.9-58.11) (OR 3.83; IC95% 3.34-4.39, p=0.0000000). Los ni\u00f1os de 1 a 2 y de 6 a 9 a\u00f1os, que a partir de 1998 formaron parte del grupo blanco de vacunaci\u00f3n vs parotiditis, tuvieron mayor seroprevalencia que el grupo de 3 a 5 a\u00f1os no vacunado. Conclusiones. La seropositividad en ni\u00f1os de 1 a 2 y de 6 a 9 a\u00f1os fue probablemente atribuible a vacunaci\u00f3n durante 1998-2000 y la de otros grupos etarios a exposici\u00f3n natural relacionada con el tiempo transcurrido en cada cohorte de nacimientos hasta el reclutamiento al estudio<\/jats:p>","DOI":"10.21149\/8138","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T17:14:35Z","timestamp":1513962875000},"page":"71","source":"Crossref","is-referenced-by-count":0,"title":["Prevalencia de anticuerpos frente a parotiditis en ni\u00f1os y adolescentes a dos a\u00f1os de haberse introducido la vacuna SRP"],"prefix":"10.21149","volume":"60","author":[{"given":"Armando","family":"M\u00e9ndez-Herrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elo\u00edsa","family":"Arias-Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"S\u00e1nchez-Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma. Leonidez","family":"Olamendi-Portugal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ruiz-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1047-3808","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"D\u00edaz-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8786","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Rubin S, Eckhaus M, Rennick LJ, Bamford CCG, Duprex WP. Molecular biology, pathogenesis and pathology of mumps virus. J Pathol. 2015;235(2):242-25. https:\/\/doi.org\/10.1002\/path.4445","DOI":"10.1002\/path.4445"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Ternavasio-de la Vega HG, Boronat M, Ojeda A, Garc\u00eda-Delgado Y, \u00c1ngel-Moreno A, Carranza-Rodr\u00edguez C, et al. Mumps Orchitis in the Post-Vaccine Era (1967 y 2009). A Single-Center Series of 67 Patients and Review of Clinical Outcome and Trends. Medicine. 2010;89(2):96-116. https:\/\/doi.org\/10.1097\/MD.0b013e3181d63191","DOI":"10.1097\/MD.0b013e3181d63191"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Werner Ca. Mumps orchitis and testicular atrophy. I. occurrence. Ann Intern Med. 1950;32(6):1066-9. https:\/\/doi.org\/10.7326\/0003-4819-32-6-1066","DOI":"10.7326\/0003-4819-32-6-1066"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Prinz W, Taubert HL. Mumps in pubescent females and its effect on later reproductive function. Gynaecologia 1969;167(1):23-27. https:\/\/doi.org\/10.1159\/000302156","DOI":"10.1159\/000302156"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/B978-1-4160-3611-1.50024-6","article-title":"Mumps vaccine.","volume-title":"Vaccines","author":"Plotkin","year":"2008","unstructured":"5. Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin SA, Orenstein W, Offit P, eds. Vaccines, 5th ed. Philadelphia: WB Saunders, 2008:435-65."},{"key":"ref5","first-page":"1776","article-title":"Mumps virus.","volume-title":"Principles and practice of infectious diseases","author":"Baum","year":"2000","unstructured":"6. Baum GB, Litman N. Mumps virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Philadelphia: Churchil Livingstone, 2000:1776-981."},{"issue":"4","key":"ref6","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome and mumps, 2013. Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","year":"2013","unstructured":"7. ACIP. Prevention of measles, rubella, congenital rubella syndrome and mumps, 2013. Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(4):1-40.","journal-title":"MMWR"},{"key":"ref7","first-page":"330","article-title":"Investigaci\u00f3n de anticuerpos inhibidores de la hemaglutinaci\u00f3n del virus de la parotiditis epid\u00e9mica en personas de diferentes edades.","volume":"21","author":"Sosa-Mart\u00ednez","year":"1964","unstructured":"8. Sosa-Mart\u00ednez J, Lira MS, Benavides L. Investigaci\u00f3n de anticuerpos inhibidores de la hemaglutinaci\u00f3n del virus de la parotiditis epid\u00e9mica en personas de diferentes edades. Bol Med Hosp Infant Mex. 1964;21:330-7.","journal-title":"Bol Med Hosp Infant Mex","ISSN":"https:\/\/id.crossref.org\/issn\/0539-6115","issn-type":"print"},{"issue":"5","key":"ref8","first-page":"603","article-title":"Anticuerpos inhibidores de la hemaglutinaci\u00f3n para sarampi\u00f3n, rub\u00e9ola y parotiditis. Investigaci\u00f3n de su prevalencia en una comunidad de la meseta de M\u00e9xico.","volume":"12","author":"Golubjatnikov","year":"1970","unstructured":"9. Golubjatnikov R, Leppla L, Filloy L. Anticuerpos inhibidores de la hemaglutinaci\u00f3n para sarampi\u00f3n, rub\u00e9ola y parotiditis. Investigaci\u00f3n de su prevalencia en una comunidad de la meseta de M\u00e9xico. Salud Publica Mex. 1970;12(5):603-9.","journal-title":"Salud Publica Mex","ISSN":"https:\/\/id.crossref.org\/issn\/0036-3634","issn-type":"print"},{"issue":"4","key":"ref9","first-page":"483","article-title":"Encuesta serol\u00f3gica en ni-os de la Ciudad de M\u00e9xico. V. Investigaci\u00f3n de anticuerpos contra la parotiditis.","volume":"13","author":"Guti\u00e9rrez","year":"1971","unstructured":"10. Guti\u00e9rrez G, Ruiz-G\u00f3mez J, Bustamante M. Encuesta serol\u00f3gica en ni-os de la Ciudad de M\u00e9xico. V. Investigaci\u00f3n de anticuerpos contra la parotiditis. Salud Publica Mex. 1971;13(4):483-7.","journal-title":"Salud Publica Mex","ISSN":"https:\/\/id.crossref.org\/issn\/0036-3634","issn-type":"print"},{"issue":"1","key":"ref10","first-page":"27","article-title":"Seroepidemiolog\u00eda del sarampi\u00f3n, rub\u00e9ola y parotiditis en la Rep\u00fablica Mexicana. V.","volume":"20","author":"Ruiz-G\u00f3mez","year":"1978","unstructured":"11. Ruiz-G\u00f3mez J, Silva-Acosta C. Seroepidemiolog\u00eda del sarampi\u00f3n, rub\u00e9ola y parotiditis en la Rep\u00fablica Mexicana. V. Parotiditis. Salud Publica Mex. 1978;20(1):27-31.","journal-title":"Parotiditis Salud Publica Mex"},{"key":"ref11","first-page":"68","volume-title":"Manual de Vacunaci\u00f3n 2008-2009 Cap\u00edtulo 4 Vacunas y toxoides","year":"2008","unstructured":"12. Consejo Nacional de Vacunaci\u00f3n. Manual de Vacunaci\u00f3n 2008-2009. Cap\u00edtulo 4. Vacunas y toxoides. M\u00e9xico: Secretar\u00eda de Salud, 2008;68-75."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Fern\u00e1ndez de Castro J, Bennett JV, Gallardo-Rinc\u00f3n H, Alvarez y Mu-oz MT, Partida-S\u00e1nchez LAE, Santos JI. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine. 2005;23(8):1079-84. https:\/\/doi.org\/10.1016\/j.vaccine.2004.08.018","DOI":"10.1016\/j.vaccine.2004.08.018"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. D\u00edaz-Ortega JL, Bennett JV, Casta-eda D, Arellano D, Martinez D, Fernandez de Castro J. Safety and antibody responses to aerosolized MMR II vaccine in adults: an exploratory study. World J Vaccines. 2012;2(2):55-60. https:\/\/doi.org\/10.4236\/wjv.2012.22008","DOI":"10.4236\/wjv.2012.22008"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. D\u00edaz-Ortega JL, Bennett JV, Casta-eda-Desales D, Arellano-Quintanilla DM, Mart\u00ednez D, Fernandez de Castro J. Booster immune response in children of 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Vaccine. 2014;32(29):3680-6. https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.031","DOI":"10.1016\/j.vaccine.2014.04.031"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Bennett JV, Fern\u00e1ndez-de Castro J, Mart\u00ednez-Poblete R, Garc\u00eda-Alc\u00e1ntara ML, Gallardo-D\u00edaz E, Molina-\u00c1ngeles MA, et al. A new rapid and promising approach to aerosol immunization: inflatable bags and valved masks. Vaccine. 2009;27(34):4571-5. https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.086","DOI":"10.1016\/j.vaccine.2009.05.086"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. D\u00edaz-Ortega JL, Bennett JV, Casta-eda D, Valdespino-G\u00f3mez JL, Fern\u00e1ndez de Castro J. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR. Vaccine. 2010;28(3):692-8. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.083","DOI":"10.1016\/j.vaccine.2009.10.083"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis. 2007;13(1):12-7. https:\/\/doi.org\/10.3201\/eid1301.060649","DOI":"10.3201\/eid1301.060649"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Kutty PK, McLean HQ, Lawler J, Schulte C, Hudson JM, Blog D, Wallace G. Risk factors for transmission of mumps in a highly vaccinated population in Orange County, NY, 2009-2010. Pediatr Infect Dis J. 2014;33(2):121-5. https:\/\/doi.org\/10.1097\/INF.0000000000000020","DOI":"10.1097\/INF.0000000000000020"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Livingston KA, Rosen JB, Zucker JR, Zimmerman CM. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine 2014;32(3):369-74. https:\/\/doi.org\/10.1016\/j.vaccine.2013.11.021","DOI":"10.1016\/j.vaccine.2013.11.021"},{"key":"ref20","first-page":"1","article-title":"Vivienda, poblaci\u00f3n y utilizaci\u00f3n de servicios de salud.","volume-title":"Encuesta Nacional de Salud 2000","author":"Valdespino","year":"2003","unstructured":"21. Valdespino JL, Olaiz G, L\u00f3pez-Barajas MP, Mendoza L, Palma O, Vel\u00e1squez O, et al. Vivienda, poblaci\u00f3n y utilizaci\u00f3n de servicios de salud. En: Encuesta Nacional de Salud 2000. Cuernavaca, Morelos: Instituto Nacional de Salud P\u00fablica, 2003:1-292."},{"key":"ref21","first-page":"43","volume-title":"M\u00e9xico","author":"Bassols-Batalla","year":"1983","unstructured":"22. Bassols-Batalla A. M\u00e9xico: Formaci\u00f3n de regiones econ\u00f3micas. Influencias, Factores y sistemas. 2\u00aa ed. Ciudad de M\u00e9xico, Instituto de Investigaciones Econ\u00f3micas de la Universidad Nacional Aut\u00f3noma de M\u00e9xico, 1983:43-71."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Sep\u00falveda J, Tapia-Conyer R, Vel\u00e1squez O, Valdespino JL, Olaiz-Fern\u00e1ndez G, Kuri P, et al. Dise-o y metodolog\u00eda de la Encuesta Nacional de Salud 2000. Salud Publica Mex. 2007;49(3):427-32. https:\/\/doi.org\/10.1590\/S0036-36342007000900015","DOI":"10.1590\/S0036-36342007000900015"},{"key":"ref23","unstructured":"11. Institut Virion\\Serion GmbH. Serion ELISA classic Mumps Virus IgG\/IgM. 2012 [citado 2016, febrero 19]. Disponible en: http:\/\/www.virion-serion.de\/en\/products\/serion-elisa-classic-kursiu\/childrens-disease\/mumps-virus.html"},{"key":"ref24","first-page":"112","volume-title":"Metodolog\u00eda de la investigaci\u00f3n epidemiol\u00f3gica","author":"Londo-o","year":"2014","unstructured":"25. Londo-o F. Metodolog\u00eda de la investigaci\u00f3n epidemiol\u00f3gica. 5\u00aa ed. Bogot\u00e1: Manual Moderno, 2014:112-27."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLos Med. 2007;4(10):e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297","DOI":"10.1371\/journal.pmed.0040297"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Ruiz-G\u00f3mez J, Valdespino JL, Olaiz-Fern\u00e1ndez G, Arias-Toledo E, Sep\u00falveda J. Encuesta serol\u00f3gica nacional del sarampi\u00f3n en ni-os: evidencias para su eliminaci\u00f3n. Salud Publica Mex. 2007;49 (supl 3):S370-6. https:\/\/doi.org\/10.1590\/S0036-36342007000900008","DOI":"10.1590\/S0036-36342007000900008"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Kutty PK, Kruszon-Moran DM, Dayan GH, Alexander JP, Williams NJ, Garcia PE, et al. Seroprevalence of antibody to mumps virus in the US population, 1999\u20132004. J Infect Dis. 2010;202(5):667-74. https:\/\/doi.org\/10.1086\/655394","DOI":"10.1086\/655394"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Santacruz-Sanmart\u00edn E, Hincapi\u00e9-Palacio D, Ospina MC, Perez-Toro O, Bernal-Restrepo LM, Buitrago-Giraldo S, et al. Seroprevalence of mumps in an epidemic period in Medell\u00edn, Colombia. Vaccine. 2015;33(42):5606-12. https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.088","DOI":"10.1016\/j.vaccine.2015.08.088"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/oso\/9780198545996.001.0001","volume-title":"Infectious diseases of humans","author":"Anderson","year":"1991","unstructured":"30.Anderson RM, May RM. Infectious diseases of humans. USA: Oxford Science Publications, 1991:12-24."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/B978-1-4160-3611-1.50075-1","article-title":"Community immunity.","volume-title":"Vaccines","author":"Fine","year":"2008","unstructured":"31. Fine PEM, Mulholland K. Community immunity. In: Plotkin SA, Orenstein W, Offit P, eds. Vaccines, 5th ed. Philadelphia: WB Saunders, 2008:1573-92."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Mackenzie DG, Hallam N, Stevenson J. Younger teenagers are also at risk of mumps outbreaks. BMJ 2005;330:1509. https:\/\/doi.org\/10.1136\/bmj.330.7506.1509","DOI":"10.1136\/bmj.330.7506.1509"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Rau CJ, Danovaro-Holliday MC. Letter to the Editor. Re: Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine. 2015;33(29):3273. https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.005","DOI":"10.1016\/j.vaccine.2014.09.005"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Del Valle A, Garc\u00eda AA, Barr\u00f3n BL. Detection of mumps virus genotype H in two previously vaccinated patients from Mexico City. Arch Virol. 2016;161(6)1639-44. https:\/\/doi.org\/10.1007\/s00705-016-2770-6","DOI":"10.1007\/s00705-016-2770-6"}],"container-title":["Salud P\u00fablica de M\u00e9xico"],"original-title":[],"link":[{"URL":"http:\/\/saludpublica.mx\/index.php\/spm\/article\/viewFile\/8138\/11351","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/saludpublica.mx\/index.php\/spm\/article\/viewFile\/8138\/11351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T01:17:18Z","timestamp":1719710238000},"score":1,"resource":{"primary":{"URL":"http:\/\/saludpublica.mx\/index.php\/spm\/article\/view\/8138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":34,"journal-issue":{"issue":"1, ene-feb","published-online":{"date-parts":[[2017,12,15]]}},"URL":"https:\/\/doi.org\/10.21149\/8138","relation":{},"ISSN":["1606-7916","0036-3634"],"issn-type":[{"type":"electronic","value":"1606-7916"},{"type":"print","value":"0036-3634"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}